Skip to content

Study · Randomized controlled trial · 2011

11 results

The impact of a gonadotropin-releasing hormone antagonist on gonadotropin ovulation induction cycles in women with polycystic ovary syndrome: a prospective randomized study.

Stadtmauer LA, Sarhan A, Duran EH, Beydoun H, Bocca S, Pultz B, Oehninger S

Fertility and sterility1 Jul 2010Cited by 17 (Europe PMC)

PMID20594551 (opens in a new tab)DOI10.1016/j.fertnstert.2010.05.023 (opens in a new tab)PepBankPUB-20594551
Source linkPubMedAsk about this study
Jump to 11 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study11

11 results from studies that gave the peptide. 11 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In women with PCOS, flexible ganirelix did not significantly improve clinical pregnancy rates versus FSH alone.

    In plain wordsIn women with PCOS, flexible ganirelix did not significantly improve clinical pregnancy rates versus FSH alone.

    Peptide
    Ganirelix
    Outcome
    No significant changeClinical pregnancy with flexible ganirelix
    Study

    n: not reported in source

    Comparator
    Recombinant FSH alone
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    Dose not stated

    Measurements

    Clinical pregnancy rate
    33%
    group 2
    Clinical pregnancy rate
    19%
    group 1

    Source sentences

    Summary
    Data are suggestive of improved CPR in group 2 versus group 1 (33% vs. 19%) and LBR (35% vs. 20%) but not significantly different.
    3 context sentences
    Summary · context
    Prospective, randomized, controlled study.
    Summary · context
    Ninety-eight anovulatory women with PCOS undergoing 154 gonadotropin OI cycles.
    Summary · context
    Patients were treated with recombinant FSH alone (group 1) or in conjunction with Ganirelix when the leading follicle was ≥13 mm (group 2) versus from the beginning of stimulation (group 3), followed by IUI.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In women with PCOS, flexible ganirelix did not significantly improve live birth rates versus FSH alone.

    In plain wordsIn women with PCOS, flexible ganirelix did not significantly improve live birth rates versus FSH alone.

    Peptide
    Ganirelix
    Outcome
    No significant changeLive birth with flexible ganirelix
    Study

    n: not reported in source

    Comparator
    Recombinant FSH alone
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    Dose not stated

    Measurements

    Live birth rate
    35%
    group 2
    Live birth rate
    20%
    group 1

    Source sentences

    Summary
    Data are suggestive of improved CPR in group 2 versus group 1 (33% vs. 19%) and LBR (35% vs. 20%) but not significantly different.
    3 context sentences
    Summary · context
    Prospective, randomized, controlled study.
    Summary · context
    Ninety-eight anovulatory women with PCOS undergoing 154 gonadotropin OI cycles.
    Summary · context
    Patients were treated with recombinant FSH alone (group 1) or in conjunction with Ganirelix when the leading follicle was ≥13 mm (group 2) versus from the beginning of stimulation (group 3), followed by IUI.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In women with PCOS, premature luteinization was lower with flexible ganirelix than FSH alone.

    In plain wordsIn women with PCOS, premature luteinization was lower with flexible ganirelix than FSH alone.

    Peptide
    Ganirelix
    Outcome
    DecreasePremature luteinization with flexible ganirelix
    Study

    n: not reported in source

    Comparator
    Recombinant FSH alone
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    Dose not stated

    Measurements

    Premature luteinization rate
    1.8%
    group 2
    Premature luteinization rate
    21%
    group 1

    Source sentences

    Summary
    Premature luteinization was highest in group 1 (21% vs. 1.8% in group 2 and 2.1% in group 3).
    3 context sentences
    Summary · context
    Prospective, randomized, controlled study.
    Summary · context
    Ninety-eight anovulatory women with PCOS undergoing 154 gonadotropin OI cycles.
    Summary · context
    Patients were treated with recombinant FSH alone (group 1) or in conjunction with Ganirelix when the leading follicle was ≥13 mm (group 2) versus from the beginning of stimulation (group 3), followed by IUI.
  4. 04HumanRandomized controlled trialEfficacy outcome

    In women with PCOS, premature luteinization was lower with ganirelix from stimulation onset than FSH alone.

    In plain wordsIn women with PCOS, premature luteinization was lower with early ganirelix than FSH alone.

    Peptide
    Ganirelix
    Outcome
    DecreasePremature luteinization with early ganirelix
    Study

    n: not reported in source

    Comparator
    Recombinant FSH alone
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    Dose not stated

    Measurements

    Premature luteinization rate
    2.1%
    group 3
    Premature luteinization rate
    21%
    group 1

    Source sentences

    Summary
    Premature luteinization was highest in group 1 (21% vs. 1.8% in group 2 and 2.1% in group 3).
    3 context sentences
    Summary · context
    Prospective, randomized, controlled study.
    Summary · context
    Ninety-eight anovulatory women with PCOS undergoing 154 gonadotropin OI cycles.
    Summary · context
    Patients were treated with recombinant FSH alone (group 1) or in conjunction with Ganirelix when the leading follicle was ≥13 mm (group 2) versus from the beginning of stimulation (group 3), followed by IUI.
  5. 05HumanRandomized controlled trialEfficacy outcome

    In women with PCOS, ganirelix from stimulation onset had a higher cancellation rate than FSH alone.

    In plain wordsIn women with PCOS, early ganirelix had a higher cancellation rate than FSH alone.

    Peptide
    Ganirelix
    Outcome
    IncreaseCancellation with early ganirelix versus FSH alone
    Study

    n: not reported in source

    Comparator
    Recombinant FSH alone
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Group 3 had the highest cancellation rate and cost without improving CPR and LBR.
    3 context sentences
    Summary · context
    Prospective, randomized, controlled study.
    Summary · context
    Ninety-eight anovulatory women with PCOS undergoing 154 gonadotropin OI cycles.
    Summary · context
    Patients were treated with recombinant FSH alone (group 1) or in conjunction with Ganirelix when the leading follicle was ≥13 mm (group 2) versus from the beginning of stimulation (group 3), followed by IUI.
  6. 06HumanRandomized controlled trialEfficacy outcome

    In women with PCOS, ganirelix from stimulation onset had a higher cancellation rate than flexible ganirelix.

    In plain wordsIn women with PCOS, early ganirelix had a higher cancellation rate than flexible ganirelix.

    Peptide
    Ganirelix
    Outcome
    IncreaseCancellation with early versus flexible ganirelix
    Study

    n: not reported in source

    Comparator
    Flexible ganirelix
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Group 3 had the highest cancellation rate and cost without improving CPR and LBR.
    3 context sentences
    Summary · context
    Prospective, randomized, controlled study.
    Summary · context
    Ninety-eight anovulatory women with PCOS undergoing 154 gonadotropin OI cycles.
    Summary · context
    Patients were treated with recombinant FSH alone (group 1) or in conjunction with Ganirelix when the leading follicle was ≥13 mm (group 2) versus from the beginning of stimulation (group 3), followed by IUI.
  7. 07HumanRandomized controlled trialOther

    In women with PCOS, ganirelix from stimulation onset cost more than FSH alone.

    In plain wordsIn women with PCOS, early ganirelix cost more than FSH alone.

    Peptide
    Ganirelix
    Outcome
    IncreaseCost with early ganirelix versus FSH alone
    Study

    n: not reported in source

    Comparator
    Recombinant FSH alone
    Outcome group
    Healthcare costs and utilization · Reproductive and sexual health
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Group 3 had the highest cancellation rate and cost without improving CPR and LBR.
    3 context sentences
    Summary · context
    Prospective, randomized, controlled study.
    Summary · context
    Ninety-eight anovulatory women with PCOS undergoing 154 gonadotropin OI cycles.
    Summary · context
    Patients were treated with recombinant FSH alone (group 1) or in conjunction with Ganirelix when the leading follicle was ≥13 mm (group 2) versus from the beginning of stimulation (group 3), followed by IUI.
  8. 08HumanRandomized controlled trialOther

    In women with PCOS, ganirelix from stimulation onset cost more than flexible ganirelix.

    In plain wordsIn women with PCOS, early ganirelix cost more than flexible ganirelix.

    Peptide
    Ganirelix
    Outcome
    IncreaseCost with early versus flexible ganirelix
    Study

    n: not reported in source

    Comparator
    Flexible ganirelix
    Outcome group
    Healthcare costs and utilization · Reproductive and sexual health
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Group 3 had the highest cancellation rate and cost without improving CPR and LBR.
    3 context sentences
    Summary · context
    Prospective, randomized, controlled study.
    Summary · context
    Ninety-eight anovulatory women with PCOS undergoing 154 gonadotropin OI cycles.
    Summary · context
    Patients were treated with recombinant FSH alone (group 1) or in conjunction with Ganirelix when the leading follicle was ≥13 mm (group 2) versus from the beginning of stimulation (group 3), followed by IUI.
  9. 09HumanRandomized controlled trialEfficacy outcome

    In women with PCOS, ganirelix from stimulation onset did not improve clinical pregnancy rates.

    In plain wordsIn women with PCOS, ganirelix from stimulation onset did not improve clinical pregnancy rates.

    Peptide
    Ganirelix
    Outcome
    Direction not reportedClinical pregnancy with early ganirelix
    Study

    n: not reported in source

    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Group 3 had the highest cancellation rate and cost without improving CPR and LBR.
    3 context sentences
    Summary · context
    Prospective, randomized, controlled study.
    Summary · context
    Ninety-eight anovulatory women with PCOS undergoing 154 gonadotropin OI cycles.
    Summary · context
    Patients were treated with recombinant FSH alone (group 1) or in conjunction with Ganirelix when the leading follicle was ≥13 mm (group 2) versus from the beginning of stimulation (group 3), followed by IUI.
  10. 10HumanRandomized controlled trialEfficacy outcome

    In women with PCOS, ganirelix from stimulation onset did not improve live birth rates.

    In plain wordsIn women with PCOS, ganirelix from stimulation onset did not improve live birth rates.

    Peptide
    Ganirelix
    Outcome
    Direction not reportedLive birth with early ganirelix
    Study

    n: not reported in source

    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Group 3 had the highest cancellation rate and cost without improving CPR and LBR.
    3 context sentences
    Summary · context
    Prospective, randomized, controlled study.
    Summary · context
    Ninety-eight anovulatory women with PCOS undergoing 154 gonadotropin OI cycles.
    Summary · context
    Patients were treated with recombinant FSH alone (group 1) or in conjunction with Ganirelix when the leading follicle was ≥13 mm (group 2) versus from the beginning of stimulation (group 3), followed by IUI.
  11. 11HumanRandomized controlled trialEfficacy outcome

    In women with PCOS, peak serum E2, total gonadotropin dose, and stimulation duration did not differ across FSH-only and ganirelix protocols.

    In plain wordsIn women with PCOS, peak E2, gonadotropin dose, and stimulation duration did not differ across FSH-only and ganirelix protocols.

    Peptide
    Ganirelix
    Outcome
    No significant changePeak serum E2, total gonadotropin dose, and stimulation duration
    Study

    n: not reported in source

    Comparator
    Across study groups
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    Dose not stated

    Source sentences

    Summary
    No differences were noted in peak serum E2, total gonadotropin dose, or days of stimulation.
    3 context sentences
    Summary · context
    Prospective, randomized, controlled study.
    Summary · context
    Ninety-eight anovulatory women with PCOS undergoing 154 gonadotropin OI cycles.
    Summary · context
    Patients were treated with recombinant FSH alone (group 1) or in conjunction with Ganirelix when the leading follicle was ≥13 mm (group 2) versus from the beginning of stimulation (group 3), followed by IUI.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:35 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.